Reduced-dose DOACs for management of high-risk elderly patients with AF
Elderly patients with atrial fibrillation (AF) remain inadequately anticoagulated despite well documented benefits of treatment with direct oral anticoagulants (DOACs). During a Daiichi Sankyo–sponsored webinar at the 29th Hong Kong College of Cardiology Annual Scientific Congress, Dr Shinya Suzuki of the Cardiovascular Institute in Tokyo, Japan, discussed the evidence for the use of DOACs, including edoxaban, in elderly patients, highlighting current data on the role of very-low-dose edoxaban in high-risk elderly patients for stroke prevention without an increased risk of bleeding compared with placebo.

New Molecule

1 New

New Indication

7 New

New Presentation

1 New

New Brand

11 New

Markings
Shape
Form
Color 1
Color 2
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in